MedTrace Logo

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-03-11

No results posted yet for this study

Summary

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)

Conditions

Interventions

BIOLOGICAL

IGN002

IGN002 is a monoclonal antibody fusion protein.

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2018-05-04
Completion
2018-05-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02519270 on ClinicalTrials.gov